Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Trial Details

NCT ID

NCT06768931

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Biolosion (oral probiotic compound preparation)

Locations (sample)

• Lanzhou, Gansu, China
• Dongguan, Guangdong, China
• Guangzhou, Guangdong, China
• Zhanjiang, Guangdong, China
• Zigong, Sichuan, China

Key Eligibility Criteria

• Women aged 1.18 years and above, diagnosed with triple-negative breast cancer (ER≤10%, PR≤10%, HER-2 negative) by pathology;
• Patients must have tumor specimens (formalin-fixed, paraffin-embedded, or fresh pre-treated tumor tissue) available for PD-L1 expression testing;
• Researchers assess indications for neoadjuvant chemotherapy, with staging from IIA to IIIC, based on imaging or pathological evaluation of cT1c, N1…
• Patients must not have received chemotherapy or targeted therapy for advanced breast cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.